SPRO$1.05+0.48%
Spero Therapeutics, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$60.86M
Float & O/S:
Inst Own:
DilutionScan read 22 of Spero Therapeutics, Inc.'s SEC filings and found 2 ATM programs and 2 shelf registrations on file for SPRO. The latest dilution event on file is a registration statement on Sep 10, 2026. Analysis updated Oct 7, 2026.
Signal8 Summary
SPRO
FDA approval met with selling
Snapshot
Spero Therapeutics is a clinical-stage biotech that successfully partnered its drug Utebzi with GSK. FY 2025 revenue jumped to $59.6M with $8.6M in net income, but Q1 2026 revenue collapsed to $258K, indicating the 2025 numbers were likely one-time collaboration milestones.
What's Happening Right Now
- : Spero and GSK received FDA approval for Utebzi to treat complicated urinary tract infections in adults.
- : Spero reported first quarter 2026 results, reaffirming a cash runway into 2028 while the FDA reviews its drug application.
